Guilin Sanjin Pharmaceutical Co., Ltd.

SZSE:002275 Stock Report

Market Cap: CN¥7.4b

Guilin Sanjin Pharmaceutical Past Earnings Performance

Past criteria checks 3/6

Guilin Sanjin Pharmaceutical has been growing earnings at an average annual rate of 0.2%, while the Pharmaceuticals industry saw earnings growing at 9.2% annually. Revenues have been growing at an average rate of 6.9% per year. Guilin Sanjin Pharmaceutical's return on equity is 12.1%, and it has net margins of 18.2%.

Key information

0.2%

Earnings growth rate

0.1%

EPS growth rate

Pharmaceuticals Industry Growth10.9%
Revenue growth rate6.9%
Return on equity12.1%
Net Margin18.2%
Next Earnings Update29 Aug 2024

Recent past performance updates

Recent updates

Guilin Sanjin Pharmaceutical (SZSE:002275) Is Due To Pay A Dividend Of CN¥0.30

May 23
Guilin Sanjin Pharmaceutical (SZSE:002275) Is Due To Pay A Dividend Of CN¥0.30

Guilin Sanjin Pharmaceutical Co., Ltd.'s (SZSE:002275) Subdued P/E Might Signal An Opportunity

May 22
Guilin Sanjin Pharmaceutical Co., Ltd.'s (SZSE:002275) Subdued P/E Might Signal An Opportunity

Does Guilin Sanjin Pharmaceutical (SZSE:002275) Deserve A Spot On Your Watchlist?

Apr 17
Does Guilin Sanjin Pharmaceutical (SZSE:002275) Deserve A Spot On Your Watchlist?

Revenue & Expenses Breakdown

How Guilin Sanjin Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

SZSE:002275 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 241,938352887118
31 Dec 232,172421921158
30 Sep 232,153402912195
30 Jun 232,158406902203
31 Mar 232,159379897220
01 Jan 231,960330817217
30 Sep 221,925375822159
30 Jun 221,857399775178
31 Mar 221,829366765209
01 Jan 221,741344723202
30 Sep 211,724265721208
30 Jun 211,694283670185
31 Mar 211,667298651158
31 Dec 201,566277626148
30 Sep 201,611367592153
30 Jun 201,602359611123
31 Mar 201,592381570133
31 Dec 191,640392628100
30 Sep 191,60037760171
30 Jun 191,61941856574
31 Mar 191,61741858969
31 Dec 181,58541357961
30 Sep 181,64948360265
30 Jun 181,64348259984
31 Mar 181,62647260266
31 Dec 171,61646461055
30 Sep 171,60042661738
30 Jun 171,5824186470
31 Mar 171,5593986480
31 Dec 161,5253946320
30 Sep 161,4954066110
30 Jun 161,4483845930
31 Mar 161,4703976070
31 Dec 151,3913775770
30 Sep 151,4084075090
30 Jun 151,4494235380
31 Mar 151,3984245000
31 Dec 141,4664455320
30 Sep 141,4234345560
30 Jun 141,4584495580
31 Mar 141,4294225360
31 Dec 131,4694225680
30 Sep 131,3993745690

Quality Earnings: 002275 has high quality earnings.

Growing Profit Margin: 002275's current net profit margins (18.2%) are higher than last year (17.5%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 002275's earnings have grown by 0.2% per year over the past 5 years.

Accelerating Growth: 002275's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 002275 had negative earnings growth (-7%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-0.8%).


Return on Equity

High ROE: 002275's Return on Equity (12.1%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.